Literature DB >> 30137303

Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases.

Nicolas Meneveau1,2, Benoit Guillon1,2, Benjamin Planquette3, Gaël Piton2,4, Antoine Kimmoun5,6, Lucie Gaide-Chevronnay7, Nadia Aissaoui8,9, Arthur Neuschwander10, Elie Zogheib11,12, Hervé Dupont11,12, Sebastien Pili-Floury2,13, Fiona Ecarnot1,2, François Schiele1,2, Nicolas Deye14,15, Nicolas de Prost16, Raphaël Favory17, Philippe Girard18, Mircea Cristinar19, Alexis Ferré20, Guy Meyer3, Gilles Capellier2,4, Olivier Sanchez3.   

Abstract

Aims: The role of extracorporeal membrane oxygenation (ECMO) remains ill defined in pulmonary embolism (PE). We investigated outcomes in patients with high-risk PE undergoing ECMO according to initial therapeutic strategy. Methods and results: From 01 January 2014 to 31 December 2015, 180 patients from 13 Departments in nine centres with high-risk PE were retrospectively included. Among those undergoing ECMO, we compared characteristics and outcomes according to adjunctive treatment strategy (systemic thrombolysis, surgical embolectomy, or no reperfusion therapy). Primary outcome was all-cause 30-day mortality. Secondary outcome was 90-day major bleeding. One hundred and twenty-eight patients were treated without ECMO; 52 (mean age 47.6 years) underwent ECMO. Overall 30-day mortality was 48.3% [95% confidence interval (CI) 41-56] (87/180); 43% (95% CI 34-52) (55/128) in those treated without ECMO vs. 61.5% (95% CI 52-78) (32/52) in those with ECMO (P = 0.008). In patients undergoing ECMO, 30-day mortality was 76.5% (95% CI 57-97) (13/17) for ECMO + fibrinolysis, 29.4% (95% CI 51-89) (5/17) for ECMO + surgical embolectomy, and 77.7% (95% CI 59-97) (14/18) for ECMO alone (P = 0.004). Among patients with ECMO, 20 (38.5%, 95% CI 25-52) had a major bleeding event in-hospital; without significant difference across groups.
Conclusion: In patients with high-risk PE, those with ECMO have a more severe presentation and worse prognosis. Extracorporeal membrane oxygenation in patients with failed fibrinolysis and in those with no reperfusion seems to be associated with particularly unfavourable prognosis compared with ECMO performed in addition to surgical embolectomy. Our findings suggest that ECMO does not appear justified as a stand-alone treatment strategy in PE patients, but shows promise as a complement to surgical embolectomy.

Entities:  

Mesh:

Year:  2018        PMID: 30137303     DOI: 10.1093/eurheartj/ehy464

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  33 in total

1.  Massive pulmonary embolism with intra-hospital cardiac arrest and full recovery of right ventricular function after veno-arterial extracorporeal membrane oxygenation therapy: a case report.

Authors:  Stephan Camen; Gerold Söffker; Stefan Kluge; Elvin Zengin
Journal:  Eur Heart J Case Rep       Date:  2020-08-03

2.  Advances in Percutaneous Management of Pulmonary Embolism.

Authors:  Jimmy Kerrigan; Michael Morse; Elias Haddad; Elisabeth Willers; Chand Ramaiah
Journal:  Int J Angiol       Date:  2022-09-02

3.  National trends and outcomes for extra-corporeal membrane oxygenation use in high-risk pulmonary embolism.

Authors:  Ayman Elbadawi; Amgad Mentias; Islam Y Elgendy; Ahmed H Mohamed; Mohammed Hz Syed; Gbolahan O Ogunbayo; Odunayo Olorunfemi; Igor Gosev; Sunil Prasad; Scott J Cameron
Journal:  Vasc Med       Date:  2019-03-05       Impact factor: 3.239

4.  Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team.

Authors:  Brett J Carroll; Sebastian E Beyer; Tyler Mehegan; Andrew Dicks; Abby Pribish; Andrew Locke; Anuradha Godishala; Kevin Soriano; Jaya Kanduri; Kelsey Sack; Inbar Raber; Cara Wiest; Isabel Balachandran; Mason Marcus; Louis Chu; Margaret M Hayes; Jeff L Weinstein; Kenneth A Bauer; Eric A Secemsky; Duane S Pinto
Journal:  Am J Med       Date:  2020-05-19       Impact factor: 4.965

5.  Hemorrhage and venous thromboembolism in critically ill patients with COVID-19.

Authors:  Chenyang Qiu; Tong Li; Guoqing Wei; Jun Xu; Wenqiao Yu; Ziheng Wu; Donglin Li; Yangyan He; Tianchi Chen; Jingchen Zhang; Xujian He; Jia Hu; Junjun Fang; Hongkun Zhang
Journal:  SAGE Open Med       Date:  2021-05-31

Review 6.  Contemporary Catheter-Based Treatment Options for Management of Acute Pulmonary Embolism.

Authors:  Maninder Singh; Irfan Shafi; Parth Rali; Joseph Panaro; Vladimir Lakhter; Riyaz Bashir
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-05-12

Review 7.  Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review.

Authors:  Catherine Ross; Riten Kumar; Marie-Claude Pelland-Marcotte; Shivani Mehta; Monica E Kleinman; Ravi R Thiagarajan; Muhammad B Ghbeis; Christina J VanderPluym; Kevin G Friedman; Diego Porras; Francis Fynn-Thompson; Samuel Z Goldhaber; Leonardo R Brandão
Journal:  Chest       Date:  2021-09-26       Impact factor: 9.410

8.  Massive pulmonary embolism in a patient with nephrotic syndrome and single lung.

Authors:  Hong Kai Shi; Shaun Chook; Lowell Leow; Shir Lynn Lim; Kollengode Ramanathan; Theo Kofidis; Giap Swee Kang
Journal:  J Thromb Thrombolysis       Date:  2021-01-02       Impact factor: 2.300

Review 9.  Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.

Authors:  Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos
Journal:  Front Cardiovasc Med       Date:  2021-07-07

Review 10.  Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action.

Authors:  Elona Rrapo Kaso; Jonathan A Pan; Michael Salerno; Alexandra Kadl; Chad Aldridge; Ziv J Haskal; Jamie L W Kennedy; Sula Mazimba; Andrew D Mihalek; Nicholas R Teman; Jay Giri; Herbert D Aronow; Aditya M Sharma
Journal:  J Cardiovasc Transl Res       Date:  2021-07-19       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.